valproic acid has been researched along with Carcinoma, Squamous Cell in 10 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage." | 6.82 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016) |
| "Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage." | 2.82 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016) |
| "Valproic acid (VPA) is a well-known drug used to treat seizure disorders and epilepsy, and has been shown to inhibit HDACs." | 1.42 | Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells. ( Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Makita, N; Miyashita, T; Nakagawara, H; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T, 2015) |
| "Growth inhibition profiles of HNSCC cell lines varied in response to VPA." | 1.38 | Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. ( Cheong, SC; Gan, CP; Hamid, S; Hor, SY; Ismail, SM; Saunders, N; Teo, SH; Wan Mustafa, WM; Zain, RB, 2012) |
| "Valproic acid (VPA) has been used in clinical practice for the treatment of epilepsy and other seizure disorders and is also one of the most represented HDAC inhibitors." | 1.38 | Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. ( Fujimura, T; Fujita, H; Fushida, S; Harada, S; Kinoshita, J; Kitagawa, H; Makino, I; Nakagawara, H; Nakamura, K; Ninomiya, I; Ohta, T; Oyama, K; Shoji, M; Tajima, H; Takamura, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, D | 1 |
| Wu, J | 1 |
| Tian, Y | 1 |
| Zhou, H | 1 |
| Zhou, Y | 1 |
| Hu, W | 1 |
| Zhao, W | 1 |
| Wei, H | 1 |
| Ling, B | 1 |
| Ma, C | 1 |
| Kang, H | 1 |
| Gillespie, TW | 1 |
| Goodman, M | 1 |
| Brodie, SA | 1 |
| Brandes, M | 1 |
| Ribeiro, M | 1 |
| Ramalingam, SS | 1 |
| Shin, DM | 1 |
| Khuri, FR | 1 |
| Brandes, JC | 1 |
| Makita, N | 1 |
| Ninomiya, I | 3 |
| Tsukada, T | 2 |
| Okamoto, K | 2 |
| Harada, S | 3 |
| Nakanuma, S | 2 |
| Sakai, S | 2 |
| Makino, I | 3 |
| Kinoshita, J | 3 |
| Hayashi, H | 2 |
| Oyama, K | 3 |
| Nakagawara, H | 2 |
| Miyashita, T | 2 |
| Tajima, H | 3 |
| Takamura, H | 3 |
| Fushida, S | 3 |
| Ohta, T | 3 |
| Kanamoto, A | 1 |
| Caponigro, F | 1 |
| Di Gennaro, E | 1 |
| Ionna, F | 1 |
| Longo, F | 1 |
| Aversa, C | 1 |
| Pavone, E | 1 |
| Maglione, MG | 1 |
| Di Marzo, M | 1 |
| Muto, P | 1 |
| Cavalcanti, E | 1 |
| Petrillo, A | 1 |
| Sandomenico, F | 1 |
| Maiolino, P | 1 |
| D'Aniello, R | 1 |
| Botti, G | 1 |
| De Cecio, R | 1 |
| Losito, NS | 1 |
| Scala, S | 1 |
| Trotta, A | 1 |
| Zotti, AI | 1 |
| Bruzzese, F | 1 |
| Daponte, A | 1 |
| Calogero, E | 1 |
| Montano, M | 1 |
| Pontone, M | 1 |
| De Feo, G | 1 |
| Perri, F | 1 |
| Budillon, A | 1 |
| Suzuki, M | 1 |
| Endo, M | 1 |
| Shinohara, F | 1 |
| Echigo, S | 1 |
| Rikiishi, H | 1 |
| Kothari, V | 1 |
| Joshi, G | 1 |
| Nama, S | 1 |
| Somasundaram, K | 1 |
| Mulherkar, R | 1 |
| Gan, CP | 1 |
| Hamid, S | 1 |
| Hor, SY | 1 |
| Zain, RB | 1 |
| Ismail, SM | 1 |
| Wan Mustafa, WM | 1 |
| Teo, SH | 1 |
| Saunders, N | 1 |
| Cheong, SC | 1 |
| Shoji, M | 1 |
| Nakamura, K | 1 |
| Fujita, H | 1 |
| Kitagawa, H | 1 |
| Fujimura, T | 1 |
| Erlich, RB | 1 |
| Rickwood, D | 1 |
| Coman, WB | 1 |
| Saunders, NA | 1 |
| Guminski, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT02624128] | Phase 2 | 39 participants (Anticipated) | Interventional | 2015-02-23 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for valproic acid and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetu | 2016 |
9 other studies available for valproic acid and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cohort Studies; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Histon | 2014 |
Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; Esophageal Neop | 2015 |
Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Movement; Cell Prolife | 2016 |
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 12; Caspase Inhibitors; Caspases, Initiator; Cell Line, | 2009 |
HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model.
Topics: Adenoviruses, Human; Animals; Bystander Effect; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined | 2010 |
Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence.
Topics: Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Differen | 2012 |
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; E | 2012 |
Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
Topics: Acetylation; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Prolifer | 2009 |